Gitnux/Report 2026

Muscle Preserving Obesity Drug Industry Statistics

The global muscle-preserving obesity therapy market was estimated at USD 20–40 million in 2026, explore the figures behind its growth, companies and trends.
14Statistics
26Sources
3Sections
1Visuals
14mRead
How this report is researched
01Editorial Scope

Gitnux editors write the brief first: the topic, the inclusion rules, and the frame for what belongs.

02Source Research

Agents search the published record and log every extracted figure back to the passage it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 28 days

01 Industry overview

The muscle preserving obesity drug industry at a glance

The muscle-preserving obesity drug industry remains an emerging clinical market, estimated at $20–40 million in 2026 and developing rapidly as companies combine incretin therapies with muscle-sparing agents.

$20–40M[2]
Estimated market size, 2026
80%[2]
Forecast CAGR, 2026–2034
54.9%[9]
Lean-mass preservation, 2025
DKK82.3B[10]
Novo obesity-care sales, 2025
Market size
The dedicated muscle-preserving obesity-therapy market was estimated at $20–40 million in 2026. The estimate covers approved or development-linked myostatin, activin and related body-composition therapies, plus associated collaborations and services; it is much smaller than the broader obesity-drug market.[2]
Forecast & CAGR
The market is forecast to expand from $20–40 million in 2026 to $2.21–4.41 billion by 2034, implying an approximately 80% CAGR. The unusually high rate reflects a very small starting base and the potential commercialization of combination therapies.[2]
Market share & regions
No reliable public source was found that reports regional market shares for muscle-preserving obesity drugs specifically. The commercial opportunity is currently concentrated in the United States, where the leading incretin market is being expanded through direct-to-patient and retail channels, while clinical development is international.[6]
Segmentation
The pipeline is segmented mainly by mechanism and combination strategy: anti-myostatin or GDF8 agents such as trevogrumab and apitegromab, anti-activin approaches, and other muscle- or body-composition therapies used with GLP-1 or GLP-1/GIP drugs. Clinical programs also span injectable antibodies, siRNA approaches and next-generation obesity medicines designed to reduce fat while preserving lean mass.[11][12][13]
Key players & concentration
The field is highly concentrated around large pharmaceutical companies and a small number of specialist biotechs. Regeneron reported phase 2 COURAGE data for trevogrumab, Scholar Rock reported phase 2 EMBRAZE data for apitegromab, and Eli Lilly has a muscle-health collaboration with Juvena Therapeutics; no reliable source provides a formal industry concentration ratio.[14][9][15]
Pricing
There are no established commercial prices for approved obesity-specific muscle-preserving add-on drugs. Their likely pricing context is set by the underlying incretin therapies: U.S. self-pay Zepbound prices listed by Lilly range from $299 to $699 per month by dose, while Wegovy's listed package price is $1,349.02.[16][17]
Trends, drivers & challenges
The main driver is concern that rapid pharmacological weight loss can include clinically important lean-mass loss: in the phase 2 COURAGE trial, semaglutide plus placebo produced a 6.6% lean-mass decrease at week 26, while trevogrumab-containing arms showed treatment differences of 2.7–4.5 percentage points. Key challenges are proving that preserved lean mass translates into durable muscle strength and function, establishing long-term safety, and securing reimbursement for combination treatment.[11][12]
Consumer behavior & competition
Competition is moving from weight loss alone toward the quality of weight loss, with companies emphasizing fat loss, lean-mass preservation, oral delivery, convenience and affordability. The broader branded GLP-1 obesity market recorded 104% global volume growth in 2025, intensifying competition for patients, prescribers and manufacturing capacity.[6][14]
M&A
No major transaction focused exclusively on a muscle-preserving obesity drug was identified in reliable public sources. Strategic activity is instead occurring through collaborations and broader obesity acquisitions; for example, Eli Lilly entered a global licensing and research collaboration with Juvena Therapeutics in June 2025 focused on muscle health and body composition in chronic diseases including obesity.[15]
Regulation
Muscle-preserving obesity candidates remain investigational and require standard clinical evidence for safety, efficacy and clinically meaningful benefit before approval. Regulatory pathways may assess both weight-management outcomes and body-composition or functional endpoints; current programs include phase 2 trials rather than approved obesity-specific muscle-preservation indications.[11][12][18]
Latest news
In November 2026, Regeneron published phase 2 COURAGE results showing that trevogrumab, with or without garetosmab, reduced lean-mass loss during semaglutide-induced weight reduction, with effects sustained through one year. In the same month, Harbour BioMed announced Chinese IND acceptance for LET003, an ACVR2A/2B-targeting antibody intended to support fat reduction while preserving or improving lean mass.[11]

02 Ranking

Top 10 Companies in the Muscle Preserving Obesity Drug Industry

The leading companies in the muscle preserving obesity drug industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 20, 2026 · Next review December 20, 2026

Verdict

Eli Lilly stands out for integrating muscle-health into obesity programs because its bimagrumab development is paired with tirzepatide for obesity and lean-mass preservation, while Novo Nordisk leads in diabetes and obesity care since it reached 45.6 million people in 2025.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in muscle-preserving obesity biologics

    Eli Lilly

    US

    Ranked #1 · 9.9 · Muscle-preserving obesity biologics

    Why we picked it: Lilly is building muscle-health integration into obesity treatment via bimagrumab with tirzepatide.

  2. #2 overall

    Novo Nordisk

    DK

    Ranked #2 · 9.1 · Muscle-preserving obesity biologics

    Why we picked it: Novo Nordisk ties muscle-preserving obesity research to a scaled diabetes and obesity care base.

  3. #3 overall

    Regeneron

    US

    Ranked #3 · 8.9 · Muscle-preserving obesity biologics

    Why we picked it: Regeneron’s Phase 2 COURAGE data links trevogrumab to reduced lean-mass loss during semaglutide.

Pick 1 is the #1 company overall. No other segment places in the top 5, so picks 2 and 3 follow rank.

Full ranking

Sort by
Top 10 companies in the muscle preserving obesity drug industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Eli Lilly

Muscle-preserving obesity biologics · US

9.9
2

Novo Nordisk

Muscle-preserving obesity biologics · DK

9.1
3

Regeneron

Muscle-preserving obesity biologics · US

8.9
4

Celltrion

Muscle-preserving obesity biologics · KR

8.5
5

Scholar Rock

Muscle-preserving obesity biologics · US

8.2
6

Sirius Therapeutics

SRSD384 siRNA for muscle-sparing obesity · CN

8.1
7

Veru

Enobosarm for GLP-1-associated muscle preservation · US

7.7
8

Wave Life Sciences

WVE-007 RNA therapy for muscle-sparing obesity · US

7.6
9

Biophytis

BIO101 muscle-function preservation with semaglutide · FR

7.3
10

iBio

IBIO-600 myostatin antibody for obesity · US

7.1

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 20, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 20). Top 10 companies in the muscle preserving obesity drug industry. In Muscle Preserving Obesity Drug Industry Statistics. Gitnux. https://gitnux.org/muscle-preserving-obesity-drug-industry-statistics/#top-companies

report visual · Breakdown

Global obesity and overweight drug market share by therapeutic category

Other obesity and overweight drugs holds the largest share at 80.6%.

19.4%
GLP-1 receptor agonists
80.6%
Other obesity and overweight drugs
source-verifiedwww1.hkexnews.hk

04 Statistics

Technology

Technology is anchored in Phase 2 programs that test muscle-preservation signals alongside incretin use; BELIEVE enrolled 507 participants across 26 sites.

R&D, patents and design rights in the muscle preserving obesity drug industry

  • 26 clinical sites participated in the Phase 2 BELIEVE study evaluating bimagrumab with or without semaglutide for muscle-preserving obesity treatment.[1]
  • 507 participants were enrolled in the Phase 2 BELIEVE study of bimagrumab with or without semaglutide for muscle-preserving obesity treatment, completed in June 2025.[1]
  • The BELIEVE program reached Phase 2, testing bimagrumab alone or with semaglutide for preservation or increase of muscle mass during obesity-related weight loss.[1]

05 Statistics

Market Intelligence

Market intelligence shows a very small 2026 base that scales into the billions by 2034, with USD 20–40 million estimated for 2026.

Market size, volume and shipments in the muscle preserving obesity drug industry

  • USD 20–40 million was the estimated global 2026 market size for muscle-preserving obesity therapy, covering approved myostatin, activin and related drugs, licensing and collaboration revenue, and related development and manufacturing services.[2]

Forecast growth and shipments in the muscle preserving obesity drug industry

  • The global muscle-preserving obesity therapy market is projected to reach USD 2.21–4.41 billion by 2034, from USD 20–40 million in 2026, under the publisher’s category definition.[2]
  • An 80% compound annual growth rate was indicated for the global muscle-preserving obesity therapy market from 2026 through 2034, under the publisher’s market definition.[2]
  • The global muscle-preserving obesity drug segment could generate more than USD 30 billion in annual sales by 2035, according to TD Cowen’s analyst estimate for adjunct treatments preserving muscle during obesity-drug weight loss.[3]

06 Statistics

Strategy & Growth

Strategy and growth data highlights deal velocity in obesity therapy and the scale of manufacturing investment, including $2.0 billion in U.S. manufacturing during 2025.

M&A and consolidation in the muscle preserving obesity drug industry

  • $20.3 billion in announced 2025 R&D partnership value covered broader obesity and diabetes therapeutics, including next-generation and muscle-preserving approaches; 23 deals were recorded globally.[4]
  • About 10 obesity-treatment deals were recorded in Q1–Q3 2025, versus approximately 2 in 2020, in Bain’s broader obesity-treatment transaction series that includes muscle-preserving drug assets.[5]
  • $10.8 billion in announced 2025 deal value covered GLP-1, GLP-1R and GIP-targeted therapeutics, a broader mechanism category containing many muscle-preserving obesity-drug combinations; 8 deals were recorded.[4]
  • $27.5 billion in obesity-treatment M&A and licensing deal value was announced in Q1–Q3 2025, covering deals above $100 million and the broader obesity category containing muscle-preserving candidates.[5]

Capacity expansion in the muscle preserving obesity drug industry

  • $2.0 billion was invested in U.S. manufacturing during 2025, with a further $5.6 billion planned through 2028 for obesity-drug lines, fill-finish, packaging and site expansion.[6]
  • $9.0 billion is the total investment committed to Eli Lilly’s Lebanon, Indiana site, including a $5.3 billion 2024 expansion to increase API capacity for tirzepatide obesity medicines.[7]
  • 3 fill-finish manufacturing sites were acquired from Catalent in 2024 and were being integrated into Novo Nordisk’s network for GLP-1 medicines, a broader category containing muscle-preserving obesity-drug combinations.[8]

Key questions about the muscle preserving obesity drug industry

What is the 2026 market size for muscle-preserving obesity therapy?
USD 20–40 million was the estimated global 2026 market size for muscle-preserving obesity therapy.
How fast is this market forecast to grow after 2026?
The market is projected to reach USD 2.21–4.41 billion by 2034, implying about an 80% CAGR from 2026 through 2034.
Which companies lead the muscle preserving obesity drug industry?
Eli Lilly stands out for integrating muscle-health into obesity programs because its bimagrumab development is paired with tirzepatide for obesity and lean-mass preservation, while Novo Nordisk leads in diabetes and obesity care since it reached 45.6 million people in 2025.
How is technology shifting in muscle-preserving obesity development?
Development is moving from weight loss alone toward combination therapy models that address lean-mass loss during incretin-based reduction.
What does the market structure look like for this niche?
The field is highly concentrated around large pharmaceutical companies and a small number of specialist biotechs, with partnerships replacing muscle-specific M&A in the available reporting.
Why do clinical programs focus on lean-mass outcomes in addition to weight loss?
In Phase 2 COURAGE, semaglutide plus placebo produced a 6.6% lean-mass decrease at week 26, while trevogrumab-containing arms showed 2.7–4.5 percentage-point treatment differences.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 20). Muscle Preserving Obesity Drug Industry Statistics. Gitnux. https://gitnux.org/muscle-preserving-obesity-drug-industry-statistics
MLA
Samuel Norberg. "Muscle Preserving Obesity Drug Industry Statistics." Gitnux, 20 Nov 2026, https://gitnux.org/muscle-preserving-obesity-drug-industry-statistics.
Chicago
Samuel Norberg. 2026. "Muscle Preserving Obesity Drug Industry Statistics." Gitnux. https://gitnux.org/muscle-preserving-obesity-drug-industry-statistics.